<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2004</study_start_year><condition>Neoplasm Metastasis</condition><condition>Liver Metastases</condition><condition>Colorectal Cancer</condition><condition>Liver Neoplasms</condition><disease>Neoplasm Metastasis</disease><disease>Liver Metastases</disease><disease>Colorectal Cancer</disease><disease>Liver Neoplasms</disease><study_type>Interventional</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2016055</full_dataset_link><location>Austria</location><location>Germany</location><study_start_month>11</study_start_month><keyword>Folic Acid</keyword><keyword>Irinotecan</keyword><keyword>Chemotherapy</keyword><keyword>Oxaliplatin</keyword><keyword>Liver resection</keyword><keyword>Resection</keyword><keyword>Levoleucovorin</keyword><keyword>Neoadjuvant</keyword><keyword>Leucovorin</keyword><keyword>Cetuximab</keyword><keyword>5-FU</keyword><keyword>Fluorouracil</keyword><repository>ECRIN MDR</repository><study_status>Completed</study_status></additional><is_claimable>false</is_claimable><name>Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)</name><description>General Objectives:
* To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection
* To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chemotherapy</description><dates><creation>2004-11-15</creation></dates><accession>2016055</accession><cross_references><ClinicalTrials___gov>NCT00153998</ClinicalTrials___gov></cross_references></HashMap>